Latest Regulatory News

Uvre Limited has completed a key Phase 2 geophysical survey at its Frome Downs Uranium Project in South Australia and secured a Heritage Survey Agreement, setting the stage for its inaugural drilling program.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Credit Corp Group Limited has announced a fully franked ordinary dividend of AUD 0.32 per share for the six months ending December 2024, signaling steady shareholder returns.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Credit Corp Group reported steady H1 FY25 results with operational improvements and confirmed full-year guidance, driven by growth in US debt buying and stable Australian/New Zealand lending.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Sandfire Resources reported a 5% increase in copper equivalent production for H1 FY25, alongside a reduction in injury rates and operating costs at its Motheo operation. The company secured key approvals for a new tailings facility at MATSA, underpinning long-term growth.

Change Financial Limited reported a robust Q2 FY25 with revenue surging 53% year-on-year, driven by its expanding PaaS platform, while strategically exiting its loss-making US operations to sharpen focus on Australia and New Zealand.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.